A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L

Tomonari Sasaki, Takashi Seto, Takeharu Yamanaka, Naonobu Kunitake, Junichi Shimizu, Takeshi Kodaira, Makoto Nishio, Takuyo Kozuka, Toshiaki Takahashi, Hideyuki Harada, Naruo Yoshimura, Shinichi Tsutsumi, Hiromoto Kitajima, Masaaki Kataoka, Yukito Ichinose, Kazuhiko Nakagawa, Yasumasa Nishimura, Nobuyuki Yamamoto, Yoichi Nakanishi, Tomonari Sasaki, Takashi Seto, Takeharu Yamanaka, Naonobu Kunitake, Junichi Shimizu, Takeshi Kodaira, Makoto Nishio, Takuyo Kozuka, Toshiaki Takahashi, Hideyuki Harada, Naruo Yoshimura, Shinichi Tsutsumi, Hiromoto Kitajima, Masaaki Kataoka, Yukito Ichinose, Kazuhiko Nakagawa, Yasumasa Nishimura, Nobuyuki Yamamoto, Yoichi Nakanishi

Abstract

Background: Cisplatin-based chemoradiotherapy is the standard treatment for unresectable, locally advanced non-small-cell lung cancer (NSCLC). This trial evaluated two experimental regimens that combine chemotherapy with concurrent radiotherapy.

Methods: Eligible patients with unresectable stage III NSCLC were randomised to either the SP arm (S-1 and cisplatin) or VP arm (vinorelbine and cisplatin), with early concurrent thoracic radiotherapy of 60 Gy, comprising 2 Gy per daily fraction. The primary endpoint was the overall survival rate at 2 years (2-year overall survival (OS)) (Study ID: UMIN000002420).

Results: From September 2009 to September 2012, 112 patients were enroled. Of the 108 eligible patients, the 2-year OS was 75.6% (80% confidence interval (CI), 67-82%) in the SP arm and 68.5% (80% CI: 60-76%) in the VP arm. The hazard ratio (HR) for death between the two arms was 0.85 (0.48-1.49). The median progression-free survival was 14.8 months for the SP arm and 12.3 months for the VP arm with an HR of 0.92 (0.58-1.44). There were four treatment-related deaths in the SP arm and five in the VP arm.

Conclusions: The null hypotheses for 2-year OS were rejected in both arms. The West Japan Oncology Group will employ the SP arm as the investigational arm in a future phase III study.

Conflict of interest statement

All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. T. Seto has received honoraria from Kyowa Hakko Kirin Co., Ltd. and Taiho Pharmaceutical Co., Ltd. T.Y. has received personal fees from Taiho Pharmaceutical Co., Ltd. N.K. has received personal fees from Taiho Pharmaceutical Co., Ltd. M.N. has received grants and personal fees from Taiho Pharmaceutical Co., Ltd. T.T. has received grants and personal fees from Taiho Pharmaceutical Co., Ltd. Y.I. has received honoraria from Kyowa Hakko Kirin Co., Ltd. and Taiho Pharmaceutical Co., Ltd. K.N. has received grants and personal fees from Taiho Pharmaceutical Co., Ltd., during the conduct of the study; grants and personal fees from Kyowa Hakko Kirin Co., Ltd. N. Yamamoto has received grants and personal fees from Kyowa Hakko Kirin Co., Ltd. and Taiho Pharmaceutical Co., Ltd. Y. Nakanishi has received grants from Taiho Pharmaceutical Co., Ltd. All other authors declared no competing interests.

Figures

Fig. 1
Fig. 1
Treatment schedule. The treatment schedule of each arm. SP arm: S-1 plus cisplatin plus thoracic radiotherapy (TRT), VP arm: vinorelbine (VNR) plus cisplatin plus thoracic radiotherapy
Fig. 2
Fig. 2
Relationship between lung V20 and radiation pneumonitis. The relationship between lung V20 and pneumonitis grading in the SP arm (S-1 plus cisplatin plus thoracic radiotherapy) and the VP arm (vinorelbine plus cisplatin plus thoracic radiotherapy). The patients are arranged in ascending order of V20 on the vertical axis and lung V20 is plotted on the horizontal axis; the grade of pneumonitis is colour coded
Fig. 3
Fig. 3
Survival curves. Kaplan–Meier estimates of a overall survival (OS; primary endpoint) in the full analysis set (FAS) and b progression-free survival (PFS) in the FAS. OS was measured from the date of random assignment to the date of death as a result of any cause. At the cutoff date for data inclusion in the analysis, if a patient had not died, OS was censored at the last date they were known to still be alive. PFS was measured from the date of random assignment to the first date of documented objective progression of disease, or of death as a result of any cause. PFS was censored at the date of the last objective progression-free disease assessment before the date of any subsequent systemic anticancer therapy or death, whichever applied first. CI confidence interval, SP arm S-1 plus cisplatin plus thoracic radiotherapy, VP arm vinorelbine plus cisplatin plus thoracic radiotherapy
Fig. 4
Fig. 4
Subset analysis. Overall survival hazard ratio in subgroups according to baseline characteristics. CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, CDDP cisplatin, VNR vinorelbine

References

    1. Torre LA, et al. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87–108. doi: 10.3322/caac.21262.
    1. Segawa Y, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J. Clin. Oncol. 2010;28:3299–3306. doi: 10.1200/JCO.2009.24.7577.
    1. Yamamoto N, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J. Clin. Oncol. 2010;28:3739–3745. doi: 10.1200/JCO.2009.24.5050.
    1. Shirasaka T, et al. Antitumor activity of 1 M tegafur–0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602–2606.
    1. Ichinose Y, et al. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706) J. Thorac. Oncol. 2011;6:2069–2075. doi: 10.1097/JTO.0b013e3182307e5a.
    1. Vokes EE, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J. Clin. Oncol. 2002;20:4191–4198. doi: 10.1200/JCO.2002.03.054.
    1. Zatloukal P, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 2004;46:87–98. doi: 10.1016/j.lungcan.2004.03.004.
    1. Sekine I, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J. Thorac. Oncol. 2006;1:810–815. doi: 10.1097/01243894-200610000-00009.
    1. Ohyanagi F, et al. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br. J. Cancer. 2009;101:225–231. doi: 10.1038/sj.bjc.6605152.
    1. Kaira K, et al. Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer. 2013;82:449–454. doi: 10.1016/j.lungcan.2013.09.004.
    1. Krzakowski M, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J. Thorac. Oncol. 2008;3:994–1002. doi: 10.1097/JTO.0b013e31818396cb.
    1. Juan O, et al. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Anticancer Res. 2014;34:1959–1966.
    1. Senan S, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2016;34:953–962. doi: 10.1200/JCO.2015.64.8824.
    1. Bradley JD, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–199. doi: 10.1016/S1470-2045(14)71207-0.
    1. Sekine I, et al. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci. 2004;95:691–695. doi: 10.1111/j.1349-7006.2004.tb03331.x.
    1. Horinouchi H, et al. Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer. Cancer Sci. 2013;104:93–97. doi: 10.1111/cas.12028.
    1. Shukuya T, et al. Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer. Anticancer Res. 2012;32:675–680.
    1. Yao L, et al. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial. Radiat. Oncol. 2015;10:10. doi: 10.1186/s13014-014-0306-3.
    1. Nogami N, et al. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501. Lung Cancer. 2015;87:141–147. doi: 10.1016/j.lungcan.2014.11.001.
    1. Hirose T, et al. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer. Cancer Chemother. Pharmacol. 2005;58:361–367. doi: 10.1007/s00280-005-0164-7.
    1. Imamura F, et al. Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB non-small-cell lung cancer. Clin. Lung Cancer. 2014;15:281–286. doi: 10.1016/j.cllc.2014.02.001.
    1. Palma DA, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2013;85:444–450. doi: 10.1016/j.ijrobp.2012.04.043.
    1. Ahn JS, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J. Clin. Oncol. 2015;33:2660–2666. doi: 10.1200/JCO.2014.60.0130.
    1. Antonia SJ, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 2017;377:1919–1929. doi: 10.1056/NEJMoa1709937.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다